© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR
Nephrology, Education and Research, Vancouver BC V6Z 1Y6, Canada
Correspondence and offprint requests to: Dr A. Levin, Nephrology, Education and Research, 1081 Burrad Street, Room 6010, Vancouver, BC V6Z 1Y6, Canada.
| The first 150 words of the full text of this article appear below. |
Two randomized control trials (RCTs), CREATE and CHOIR, recently published in the New England Journal of Medicine, have received intense attention and discussion by the nephrology community [1,2]. Anaemia and its treatment have been the focus of multiple randomized control studies in the recent past, most small and relatively short, so why this amount of discussion now [3–7]?
These two new studies by Drueke et al. [1] and Singh et al. [2] represent the largest studies in non-dialysis patients published to date; they both tested the hypothesis that higher haemoglobin would lead to improved patient outcomes, and both were negative.
The purpose of this editorial is to critically review the two studies, with special attention to the methodology and analysis of both, and by so doing to understand what we can and cannot conclude from them. Importantly,
 |
What do we actually know to date from CREATE and CHOIR? |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. C. Macdougall, C. R.V. Tomson, M. Steenkamp, and D. Ansell Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up Nephrol. Dial. Transplant., November 23, 2009; (2009) gfp550v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, and D. J. van Veldhuisen The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure Eur J Heart Fail, November 1, 2009; 11(11): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Singh, J. Himmelfarb, and L. A. Szczech Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1436 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chonchol, G. Lippi, M. Montagnana, M. Muggeo, and G. Targher Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2879 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ishani, C. A. Solid, E. D. Weinhandl, D. T. Gilbertson, R. N. Foley, and A. J. Collins Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1682 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Furumatsu, Y. Nagasawa, T. Hamano, H. Iwatani, K. Iio, T. Shoji, T. Ito, Y. Tsubakihara, and E. Imai Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan Nephrol. Dial. Transplant., March 1, 2008; 23(3): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Moranne, L. Watier, J. Rossert, B. Stengel, and The GN-Progress Study Group Primary glomerulonephritis: an update on renal survival and determinants of progression QJM, March 1, 2008; 101(3): 215 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Ghali, I. S. Anand, W. T. Abraham, G. C. Fonarow, B. Greenberg, H. Krum, B. M. Massie, S. M. Wasserman, M.-L. Trotman, Y. Sun, et al. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia Circulation, January 29, 2008; 117(4): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. B. O'Mara Anemia in Patients With Chronic Kidney Disease Diabetes Spectr, January 1, 2008; 21(1): 12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall, K.-U. Eckardt, and F. Locatelli Latest US KDOQI Anaemia Guidelines update what are the implications for Europe? Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2738 - 2742. [Full Text] [PDF]
|
|
|
|
|
|
N. Kutner Quality of life assessment in a recent haemoglobin trial in CKD (CHOIR) Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2099 - 2099. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Singh, L. Szczech, K. L. Tang, H. Barnhart, S. Sapp, M. Wolfson, and D. Reddan Anaemia of CKD--the CHOIR study revisited Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1806 - 1810. [Full Text] [PDF]
|
|
|
|
|
|
P. Barany and H.-J. Muller Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv10 - iv18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ingelfinger Through the Looking Glass: Anemia Guidelines, Vested Interests, and Distortions Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 415 - 417. [Full Text] [PDF]
|
|